Osteopore secures Middle East distribution deal across five GCC markets
Osteopore Limited (ASX: OSX) has signed a 3-year distribution agreement with Al-Umnia Medical LLC covering its orthopaedic bone reconstruction products across Saudi Arabia, the United Arab Emirates, Oman, Qatar and Bahrain. Announced on 6 August 2026, the agreement marks a strategic geographic expansion of the product line beyond South East Asia into the Middle East.
The move opens access to the Gulf Cooperation Council (GCC) orthopaedic devices market, valued at approximately USD 897.5 million in 2025. The agreement runs for an initial three years with an option for a further one-year extension.
When big ASX news breaks, our subscribers know first
Inside the Al-Umnia distribution agreement
The deal appoints Al-Umnia as distributor of Osteopore’s orthopaedic bone reconstruction range across the five listed markets. Under the terms, both parties will now proceed with product registration in each of the five countries, according to each country’s requirements and practice.
Founded in Dubai in 2009 as a four-member team, Al-Umnia has grown into a 70+ strong, multi-department organisation focused on building partnerships with international medical technology suppliers across the GCC region. According to the announcement, the company has recorded annual sales turnover of more than EUR 10m since 2023.
| Term | Detail |
|---|---|
| Product segment | Orthopaedic bone reconstruction |
| Period | 3 years, with option of a further 1-year extension |
| Countries | Saudi Arabia, UAE, Oman, Qatar, Bahrain |
| Termination clause | Related to non-performance of sales purchase targets |
Why the GCC market matters for Osteopore
The commercial rationale centres on market size and structural demand. The GCC orthopaedic devices market is forecast to grow at a 6.04% CAGR, underpinned by demographic and clinical trends specific to the region.
Key data points from the announcement include:
-
GCC orthopaedic devices market valued at approximately USD 897.5 million in 2025, forecast to reach USD 1.55 billion by 2034 (6.04% CAGR)
-
The UAE is the largest single market at a 31.5% share
-
Synthetic bone substitutes form a distinct segment within this market
-
Age-standardised incidence of lower-extremity fractures across the Middle East and North Africa rose 4.57% between 1990 and 2019, contrary to the declining global trend
-
Saudi Arabia records the highest age-standardised fracture incidence in the region at 2,010.56 per 100,000 population
Osteopore’s Saudi Arabia craniofacial market access, secured through the Zimmer Biomet distribution channel in July 2026, means the Kingdom now hosts two separate product lines from the company, with orthopaedic bone reconstruction joining an already active craniofacial implant presence.
-
Saudi Arabia recorded 63,737 road traffic accidents between 2016 and 2020, concentrated in Riyadh and Makkah
-
Approximately 80% of bone sarcomas arise in the femur, tibia, humerus and pelvis
For investors, rising fracture incidence in a young, working-age population combined with a growing market provides a demand backdrop for Osteopore’s bone regeneration products, subject to the completion of registration in each jurisdiction.
Understanding Osteopore’s regenerative bone technology
Osteopore is an Australian-Singaporean regenerative medicine company that commercialises products designed to enable natural bone healing. Its patented technology fabricates micro-structured scaffolds through 3D printing using a bioresorbable polymer that naturally dissolves over time, allowing natural and healthy bone tissue to regenerate. According to the company, this significantly reduces the post-surgery complications commonly associated with permanent bone implants. This is the technology Al-Umnia will distribute across the GCC.
Osteopore’s bioresorbable scaffold technology in clinical use was demonstrated most recently in Hainan, where a 12cm upper-limb bone defect in a paediatric patient was reconstructed using the same scaffold design principle that Al-Umnia will distribute across the GCC, with the regenerative approach chosen specifically to avoid the lifetime revision surgeries associated with permanent implants.
Key differentiators highlighted by Osteopore include:
-
Patented, patent-protected scaffolds
-
A proprietary manufacturing technique
-
3D printing technology described as unique to Osteopore
-
Bioresorbable material that dissolves over time
Management commentary
Dr Yujing Lim, Chief Executive Officer
“Our orthopaedics bone reconstruction product line is now progressing to the next phase of commercialisation – beyond South East Asia to the Middle East.
“We are delighted to partner with Al-Umnia, who have a strong presence in the region with an organisation structure focused on clinical education, training, and support,” said Dr Lim.
What comes next for Osteopore
The immediate next step is product registration across the five GCC countries, which serves as the gateway to sales. The agreement builds on Osteopore’s existing South East Asia base, extending its commercialisation footprint into a new region through a staged approach.
Near-term milestones under the agreement include:
-
Proceeding with product registration in each of the five GCC countries, according to local requirements and practice
-
An initial term of three years, with a potential one-year extension
The entry into the GCC positions the Middle East as the next stage in Osteopore’s broader geographic commercialisation strategy.
Don’t Miss the Next Healthcare Breakthrough in Your Inbox
Get FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis, the moment announcements hit the market. Join 20,000+ investors already using Big News Blast to stay ahead of market-moving developments. Click the “Free Alerts” button to start receiving real-time coverage across ASX healthcare and beyond.